
    
      This is an open-label extension of parent studies ABI-H0731-201 (NCT03576066) and
      ABI-H0731-202 (NCT03577171). The extension study will assess the safety of long-term (up to
      100 weeks of treatment in extension study ABI-H0731-211) combination therapy and its effect
      on biomarkers of sustained viral response (SVR).
    
  